Background Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being even more obscure when it is associated to...
-
September 6, 2022 (v1)PublicationUploaded on: December 4, 2022
-
October 31, 2022 (v1)Publication
Background There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months. Methods EGFR mutated stage IIIB and IV NSCLC patients diagnosed between January 2009 and December 2017...
Uploaded on: December 4, 2022 -
November 2, 2022 (v1)Publication
Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. Herein, seven methodologies including two next-generation sequencing (NGS)-based methods, three high-sensitivity...
Uploaded on: December 4, 2022 -
July 21, 2023 (v1)Publication
Background: The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immuno‑ therapy itself. This work aims to study the situation of biomarker testing in Spain. Patients and methods: The...
Uploaded on: October 11, 2023 -
October 14, 2022 (v1)Publication
Background Pneumonitis (Pn) is one of the main immune-related adverse effects, having a specialimportance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being even more obscure when it is associated to...
Uploaded on: March 24, 2023 -
November 9, 2023 (v1)Publication
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported. METHODS This was an open-label, multicenter,...
Uploaded on: November 25, 2023 -
December 5, 2022 (v1)Publication
Background:Immunotherapy is being tested in early-stage non-small cell lungcancer (NSCLC), and achieving higher rates of complete pathological responses(CPR) as compared to standard of care. Early identification of CPR patients hasvital clinical implications. In this study, we focused on basal peripheral immunecells and their treatment-related...
Uploaded on: March 24, 2023 -
September 27, 2022 (v1)Publication
Purpose: Characterization of the T-cell receptor (TCR) reper- toire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non– small cell lung cancer (NSCLC). Experimental Design: In this study, next-generation TCR sequencing was performed in peripheral blood and tissue sam- ples of 40...
Uploaded on: March 24, 2023 -
February 29, 2024 (v1)Publication
The new lymphoma classifcations (International Consensus Classifcation of Mature Lymphoid Neoplasms, and 5th World Health Organization Classifcation of Lymphoid Neoplasms) include genetics as an integral part of lymphoma diagnosis, allowing better lymphoma subclassifcation, patient risk stratifcation, and prediction of treatment response....
Uploaded on: March 3, 2024 -
October 5, 2022 (v1)Publication
The search of prognostic factors is a priority in diffuse large B-cell lymphoma (DLBCL) due to its aggressiveness. We have recently found that the level of circulating MDSCs is a good marker of survival in a translational study based on a trial (EudraCT Number: 2014-001620-29), using lenalidomide combined with R-GDP (rituximab plus gemcitabine,...
Uploaded on: December 4, 2022